{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:00:12Z","timestamp":1792699212200,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.virusres.2016.11.020","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T20:48:16Z","timestamp":1479934096000},"page":"166-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Developments in L2-based human papillomavirus (HPV) vaccines"],"prefix":"10.1016","volume":"231","author":[{"given":"Christina","family":"Schellenbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.S.","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Kirnbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2016.11.020_bib0005","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1073\/pnas.0800868105","article-title":"Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2","volume":"105","author":"Alphs","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virusres.2016.11.020_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.virol.2010.02.002","article-title":"Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments","volume":"401","author":"Bernhard","year":"2010","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2016.11.020_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00449-16","article-title":"Broad cross protection is induced by a human papillomavirus vaccine composed of L1\/L2 chimeric virus-like particles in preclinical models","volume":"90","author":"Boxus","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0020","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/JVI.69.6.3959-3963.1995","article-title":"Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0025","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"Bruni","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2016.11.020_bib0030","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/JVI.78.2.751-757.2004","article-title":"Efficient intracellular assembly of papillomaviral vectors","volume":"78","author":"Buck","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0035","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1016\/j.vaccine.2010.04.049","article-title":"Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7","volume":"28","author":"Caldeira","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0040","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1006\/viro.1997.8649","article-title":"A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease","volume":"234","author":"Campo","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2016.11.020_bib0045","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16 18 and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2016.11.020_bib0050","doi-asserted-by":"crossref","DOI":"10.1006\/viro.1995.1392","article-title":"Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4","volume":"211","author":"Chandrachud","year":"1995","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2016.11.020_bib0055","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1097-2765(00)80449-9","article-title":"Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16","volume":"5","author":"Chen","year":"2000","journal-title":"Mol. Cell"},{"key":"10.1016\/j.virusres.2016.11.020_bib0060","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/0042-6822(91)90890-N","article-title":"The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes","volume":"181","author":"Christensen","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2016.11.020_bib0065","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/sj.bjc.6605611","article-title":"Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia","volume":"102","author":"Daayana","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.virusres.2016.11.020_bib0070","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1128\/JVI.72.1.142-150.1998","article-title":"The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription\/replication protein, E2, to PML oncogenic domains","volume":"72","author":"Day","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0075","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1128\/CVI.00139-12","article-title":"A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies","volume":"19","author":"Day","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0080","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"De Sanjose","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0085","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/S0264-410X(02)00350-X","article-title":"Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine","volume":"20","author":"De Jong","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"De Villiers","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2016.11.020_bib0095","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18\u201345 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum. Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0100","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.4161\/hv.36117","article-title":"Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine and HPV-6\/11\/16\/18 vaccine in healthy women aged 18\u201345 years: follow-up through Month 48 in a Phase III randomised study","volume":"10","author":"Einstein","year":"2014","journal-title":"Hum. Vaccine Immunother."},{"key":"10.1016\/j.virusres.2016.11.020_bib0105","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/sti.2009.037788","article-title":"Rapid decline in presentations for genital warts after the implementation of a national quadrivalent human papillomavirus vaccination program for young women","volume":"85","author":"Fairley","year":"2009","journal-title":"Sex. Transm. Infect."},{"key":"10.1016\/j.virusres.2016.11.020_bib0110","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1525-1438.2006.00598.x","article-title":"Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial","volume":"16","author":"Fiander","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.virusres.2016.11.020_bib0115","doi-asserted-by":"crossref","first-page":"11120","DOI":"10.1158\/0008-5472.CAN-06-2560","article-title":"Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species","volume":"66","author":"Gambhira","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.virusres.2016.11.020_bib0120","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1128\/JVI.01577-07","article-title":"Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0125","doi-asserted-by":"crossref","first-page":"13927","DOI":"10.1128\/JVI.00936-07","article-title":"A protective and broadly cross-neutralizing epitope of human papillomavirus L2","volume":"81","author":"Gambhira","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0130","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1099\/0022-1317-77-7-1577","article-title":"Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies","volume":"77","author":"Gaukroger","year":"1996","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1099\/0022-1317-77-2-183","article-title":"Antigenicity of bovine papillomavirus type 1 (BPV-1) L1 virus-like particles compared with that of intact BPV-1 virions","volume":"77","author":"Ghim","year":"1996","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0140","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1073\/pnas.95.4.1800","article-title":"Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model","volume":"95","author":"Greenstone","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virusres.2016.11.020_bib0145","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.67.1.315-322.1993","article-title":"Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins","volume":"67","author":"Hagensee","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0150","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/vaccines3020408","article-title":"Gavi HPV programs: application to implementation","volume":"3","author":"Hanson","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.virusres.2016.11.020_bib0155","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(14)70481-4","article-title":"Present status of human papillomavirus vaccine development and implementation","volume":"16","author":"Herrero","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0160","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/j.ajog.2008.03.064","article-title":"The economic burden of noncervical human papillomavirus disease in the United States","volume":"198","author":"Hu","year":"2008","journal-title":"Am. J. Obs. Gynecol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120152","article-title":"A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types","volume":"10","author":"Huber","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2016.11.020_bib0170","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djp106","article-title":"Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines","volume":"101","author":"Jagu","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.virusres.2016.11.020_bib0175","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1128\/JVI.03218-12","article-title":"Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine","volume":"87","author":"Jagu","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0180","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1016\/j.vaccine.2015.09.005","article-title":"Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17\u201336 epitopes","volume":"33","author":"Jagu","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0185","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1158\/1055-9965.EPI-14-0410","article-title":"Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease","volume":"23","author":"Joura","year":"2014","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.virusres.2016.11.020_bib0190","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2016.11.020_bib0195","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1016\/j.vaccine.2014.04.032","article-title":"Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes","volume":"32","author":"Kalnin","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1006\/viro.1998.9168","article-title":"A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2","volume":"245","author":"Kawana","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2016.11.020_bib0205","doi-asserted-by":"crossref","first-page":"6188","DOI":"10.1128\/JVI.73.7.6188-6190.1999","article-title":"Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6","volume":"73","author":"Kawana","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0210","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0264-410X(00)00367-4","article-title":"Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies","volume":"19","author":"Kawana","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0215","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1128\/JVI.75.5.2331-2336.2001","article-title":"Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm","volume":"75","author":"Kawana","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0220","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1016\/S0264-410X(03)00454-7","article-title":"Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers","volume":"21","author":"Kawana","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0225","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.vaccine.2007.11.019","article-title":"Generation and characterization of a preventive and therapeutic HPV DNA vaccine","volume":"26","author":"Kim","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0230","doi-asserted-by":"crossref","first-page":"20458","DOI":"10.1073\/pnas.0908502106","article-title":"The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding","volume":"106","author":"Kines","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virusres.2016.11.020_bib0235","first-page":"12180","article-title":"Papillomavirus Li major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Med. Sci."},{"key":"10.1016\/j.virusres.2016.11.020_bib0240","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1128\/JVI.67.12.6929-6936.1993","article-title":"Efficient self-assembly of human papillomavirus type 16 LI and L1-L2 into virus-like particles","volume":"67","author":"Kirnbauer","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0245","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/jmv.21124","article-title":"Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes","volume":"80","author":"Kondo","year":"2008","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0250","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.virusres.2016.11.020_bib0255","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1470-2045(15)00047-9","article-title":"Efficacy of fewer than three doses of an HPV-16\/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials","volume":"16","author":"Kreimer","year":"2015","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0260","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1086\/314616","article-title":"Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts","volume":"179","author":"Lacey","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2016.11.020_bib0265","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1468-3083.2010.03814.x","article-title":"Prevalence of benign cutaneous disease among Oxford renal transplant recipients","volume":"25","author":"Lally","year":"2011","journal-title":"J. Eur. Acad. Dermatology Venereol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0275","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-11-0542","article-title":"Reducing HPV-associated cancer globally the burden of HPV-associated cancer in the developing versus","volume":"5","author":"Lowy","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.virusres.2016.11.020_bib0280","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Mu\u00f1oz","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.virusres.2016.11.020_bib0285","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jnci\/djp534","article-title":"Impact of human papillomavirus (HPV)-6\/11\/16\/18 vaccine on all HPV-associated genital diseases in young women","volume":"102","author":"Mu\u00f1oz","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.virusres.2016.11.020_bib0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039741","article-title":"Development of AAVLP(HPV16\/31L2) particles as broadly protective HPV vaccine candidate","volume":"7","author":"Nieto","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2016.11.020_bib0295","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.virusres.2016.11.020_bib0300","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1016\/j.vaccine.2006.04.058","article-title":"Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes","volume":"24","author":"Palmer","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0305","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.virol.2005.04.011","article-title":"Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2","volume":"337","author":"Pastrana","year":"2005","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2016.11.020_bib0310","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jmb.2008.04.049","article-title":"Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2","volume":"380","author":"Peabody","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0315","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2045-3701-4-11","article-title":"Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells","volume":"4","author":"Peng","year":"2014","journal-title":"Cell Biosci."},{"key":"10.1016\/j.virusres.2016.11.020_bib0320","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1073\/pnas.0508815103","article-title":"Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection","volume":"103","author":"Richards","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.virusres.2016.11.020_bib0325","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1006\/viro.2000.0272","article-title":"Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes","volume":"270","author":"Roden","year":"2000","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2016.11.020_bib0330","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JVI.67.4.1936-1944.1993","article-title":"Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles","volume":"67","author":"Rose","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0335","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.vaccine.2009.01.102","article-title":"Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20\u201338) peptide displayed on bacterial thioredoxin","volume":"27","author":"Rubio","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0340","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1470-2045(15)00414-3","article-title":"Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study","volume":"17","author":"Sankaranarayanan","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0345","doi-asserted-by":"crossref","first-page":"10085","DOI":"10.1128\/JVI.01088-09","article-title":"Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines","volume":"83","author":"Schellenbacher","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0350","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1038\/jid.2013.253","article-title":"Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses","volume":"133","author":"Schellenbacher","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0355","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1158\/1940-6207.CAPR-15-0164","article-title":"Robust in vitro and in vivo neutralization against multiple high-risk HPV types induced by a thermostable thioredoxin-l2 vaccine","volume":"8","author":"Seitz","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.virusres.2016.11.020_bib0360","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1099\/0022-1317-82-11-2799","article-title":"Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops","volume":"82","author":"Slupetzky","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0365","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-0378(01)00113-9","article-title":"Immunobiology of papillomavirus infections","volume":"52","author":"Stanley","year":"2001","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0370","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0264-410X(98)00146-7","article-title":"Phase I safety and antigenicity of TA-GW: A recombinant HPV6 L2E7 vaccine for the treatment of genital warts","volume":"17","author":"Thompson","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0375","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.4161\/hv.27925","article-title":"Comparison of the immunogenicity of Cervarix\u00ae and Gardasil\u00ae human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults","volume":"10","author":"Toft","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.virusres.2016.11.020_bib0380","doi-asserted-by":"crossref","first-page":"L2","DOI":"10.1371\/journal.pone.0023310","article-title":"A Pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein","volume":"6","author":"Tumban","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2016.11.020_bib0385","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049751","article-title":"VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus","volume":"7","author":"Tumban","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2016.11.020_bib0390","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1016\/j.vaccine.2015.05.016","article-title":"Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2","volume":"33","author":"Tumban","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.virusres.2016.11.020_bib0395","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1365-2133.2009.09160.x","article-title":"Warts in primary schoolchildren: prevalence and relation with environmental factors","volume":"161","author":"Van Haalen","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0400","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1086\/498164","article-title":"Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination","volume":"192","author":"Vandepapeliere","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.virusres.2016.11.020_bib0405","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1128\/JVI.77.15.8386-8393.2003","article-title":"Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16","volume":"77","author":"Varsani","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0410","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virol.2013.10.038","article-title":"Preparation and properties of a papillomavirus infectious intermediate and its utility for neutralization studies","volume":"449","author":"Wang","year":"2014","journal-title":"Virology"},{"key":"10.1016\/j.virusres.2016.11.020_bib0415","article-title":"Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV pseudovirions","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2016.11.020_bib0420","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1128\/CVI.00799-14","article-title":"Seroepidemiology of human papillomavirus 16 (HPV16) L2 and generation of L2-specific human chimeric monoclonal antibodies","volume":"22","author":"Wang","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0425","doi-asserted-by":"crossref","first-page":"e1005243","DOI":"10.1371\/journal.ppat.1005243","article-title":"Immunologic control of Mus musculus papillomavirus type 1","volume":"11","author":"Wang","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.virusres.2016.11.020_bib0430","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12985-015-0364-7","article-title":"Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach","volume":"12","author":"Wu","year":"2015","journal-title":"Virol. J."},{"key":"10.1016\/j.virusres.2016.11.020_bib0435","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1128\/JVI.77.6.3531-3541.2003","article-title":"Cell surface-binding motifs of L2 that facilitate papillomavirus infection","volume":"77","author":"Yang","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.virusres.2016.11.020_bib0440","doi-asserted-by":"crossref","first-page":"12546","DOI":"10.1074\/jbc.M208691200","article-title":"Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection","volume":"278","author":"Yang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.virusres.2016.11.020_bib0445","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.vaccine.2012.03.009","article-title":"Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb\/c mice","volume":"30","author":"Yoon","year":"2012","journal-title":"Vaccine"}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170216305287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170216305287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T13:22:52Z","timestamp":1601212972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170216305287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":89,"alternative-id":["S0168170216305287"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2016.11.020","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developments in L2-based human papillomavirus (HPV) vaccines","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2016.11.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}